Growing prevalence of various types of cancer such as carcinoma, sarcoma, etc. and increasing awareness regarding the drawback of chemotherapy are few factors which are expected to boost NDDS in cancer therapy market. Additionally, growing demand for ART for the patients suffering from HIV/AIDS, changing lifestyles such as high tobacco and alcohol consumption and rising demand for novel drug delivery systems such as transdermal patches are the high impact rendering drivers for the growth of this market. Furthermore, rising awareness among healthcare professionals regarding benefits associated with nanoparticles & embrolic agents and technological advancement such as incorporation of nanotechnology in drug delivery system, vaccine drug delivery system & prodrugs for targeted drug delivery are few factors expected to positively reinforce NDDS in cancer therapy market over the forecast period.
To request a sample copy or view summary of this report, click the link below:
On the basis of technologies the market is segmented into liquid embrolic, nanoparticles and embolization particles. In 2014, Nanoparticles was one of the highest revenue generating technological segment. Key factors attributing to its large share include growing demand for protecting the drugs from being damaged before reaching the specified area, easy diagnosis by the oncologist to observe how well they are working and preventing the drug interaction with the normal cells or tissues. Nanoparticles used for cancer therapy include DepoCyt (liposomal cytarabine), Megace ES (megestrol acetate), Abraxane (paclitaxel), Doxil (doxorubicin), Myocet (doxorubicin) and DaunoXome (daunorubicin citrate). Embolization particles are further segmented into PVA particles, microspheres, drug eluting beds (DEB), microspheres, radioembolization microspheres/selective internal radiation therapy (SIRT).